Stock Spotlights Archives - Page 14 of 20

MondaySep 26, 2022 3:39 pm

TinyGemsBreaks – Cepton Inc.’s (NASDAQ: CPTN) Short-Range Lidar Solution Aims to Bring Safety Benefits to Everyone on the Road

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of lidar-based solutions for autonomous vehicles (“AV”), advanced driver assistance systems (“ADAS”) and smart technology spaces, is leading the way with Nova, an award-winning short-range lidar solution that’s lightweight, flexible, energy-efficient, and easy to integrate into passenger and commercial vehicles. “CPTN recently announced the company’s collaboration with ZKW Group GmbH to demonstrate Nova at the IAA Transportation Conference… Cepton’s exhibit demonstrated how Nova helps eliminate blind spots and create a ‘safety cocoon’ around the vehicle by combining high-resolution, superior field of view coverage in all directions. Nova’s super-compact form additionally features flexible options…

WednesdaySep 21, 2022 12:10 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes further details on additional conferences and the participation schedule for Drysdale and additional members of Cybin’s management team in panel discussions and presentations. The additional events include the Interdisciplinary Conference on Psychedelic Research, Sept. 22-24,…

FridaySep 16, 2022 1:45 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (‘NBTS’) estimates that over 10,000 individuals with GBM succumb to the disease annually. GBM has a five-year survival rate of…

FridaySep 16, 2022 1:26 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Leading Way in Scaling up Lidar for Mass-Market Deployments

Cepton (NASDAQ: CPTN) has, since its inception, sought to market the concept of “Lidar for Life,” introducing the use of lidar technology in mass-market consumer vehicles as well as the development of smart infrastructure in cities, spaces and industrial robotics. “As a pivotal part of its efforts in promoting lidar technology across different sectors, the company has invested in making lidar a truly scalable and accessible technology – cost efficient, reliable and easy to integrate into various systems,” a recent article reads. “Through its significant ADAS lidar series production award with Koito on the General Motors business, Cepton is leading…

FridaySep 16, 2022 12:52 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Rides on Horizontal, Vertical Growth to Log Best Revenue Quarter Ever

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, has weathered the geopolitical drama and international upheaval that fueled recession concerns amid spiking inflation. None of that stopped the company from having its best revenue quarter ever, spearheaded by horizontal and vertical growth. “The Las Vegas-based company logged record revenues exceeding $9 million in the quarter, an improvement of approximately 177% from $3.25 million in the comparable quarter of fiscal 2021,” a recent article reads. “Meaningful progress in both its flagship business-to-business (‘B2B’) and new business-to-consumer (‘B2C’) divisions undergirded the jump in revenue.…

ThursdaySep 15, 2022 1:35 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a discussion of underlying logic-based evaluations that offer a realistic framework of expectations that investors can use in their analysis. “One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (‘FDA’), there are five steps to the drug development process: discovery and development, preclinical research, clinical research, FDA drug review, and,…

WednesdaySep 14, 2022 12:35 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a ‘may proceed’ letter and Investigational New Drug Application (‘IND’) clearance from the U.S.…

MondaySep 12, 2022 10:00 am

TinyGemsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) Acquisition of Controlling Stake in Bollinger Motors Featured in Recent Articles

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, was featured in recent articles published by InsideEVs and Newsweek that discussed its strategic move to purchase a controlling stake in Bollinger Motors. “EV fresh face Mullen Automotive has purchased a 60% controlling stake in Bollinger Motors for $148.2 million USD cash. It’s the company’s first EV acquisition after having purchased many of its building blocks from other enterprises along the way,” reads the Newsweek publication. The article quotes David Michery, CEO and chairman of Mullen Automotive, stating, “Combining Bollinger’s vehicles with our existing class 1 and class 2 EV…

ThursdaySep 08, 2022 1:39 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. “After a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S.…

TuesdayAug 30, 2022 1:38 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Positioned ‘Front and Center for Last-Mile Delivery Opportunities’

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, owns and partners with several synergistic businesses to create clean and scalable EVs and energy solutions. “The company’s ability to reach this goal can perhaps be measured by its success, which was recently on display when Mullen inked a deal with DelPack Logistics LLC (‘DPL’) for up to 600 Mullen Class 2 Electric Cargo Vans. The two companies entered a binding agreement calling for DPL, an Amazon delivery service partner, to purchase the EVs over the next 18 months; the first 300 will be ready for delivery by Nov. 30,…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: Stock Spotlights